Pegfilgrastim 6 mg versus 12 mg for Autologous Stem Cell Mobilization in Multiple Myeloma Patients

Pegfilgrastim (PEG) is a superior hematopoietic cell mobilizing agent in autologous stem cell transplant in Multiple Myeloma (MM) patients. While most institutions use PEG 12 mg, we have conducted a retrospective analysis comparing the performance of PEG 12 mg (pre change) and PEG 6 mg (post change) for mobilization of hematopoietic progenitor cells in patients with MM.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research